

BONESUPPORT - Positively reviewed long-term outlooks

Redeye raises its fair value range following a review of BONESUPPORT's long-term potential. Our updated and lengthened financial forecast better reflects the company's strong value proposition, which we believe positions CERAMENT well for becoming a paradigm shift driver towards locally eluting antibiotic synthetic bone grafts in bone defect treatment.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Attachments

[BONESUPPORT - Positively reviewed long-term outlooks](#)